CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)
Abstract
Authors
S Van Hoorenbeeck A Uhrlandt T Lawrence O Watkins WC Lim J Ferrer Rodriguez C Jones